User login
Key clinical point: Replacing anthracycline with fractional docetaxel in the epirubicin, oxaliplatin, and capecitabine (EOX) regimen does not improve survival and increases toxicities in chemotherapy-naive patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer.
Major finding: At data cutoff of interim analysis, no significant difference was reported between the two treatment groups in progression-free survival (hazard ratio [HR] 0.975; P = .885) and overall survival (HR 1.002; P = .992). Treatment modification (91% vs. 78%; P = .017) and grade ≥3 adverse event rates (51% vs. 43%) were higher in the docetaxel vs. EOX group.
Study details: This study was a randomized, parallel group, open-label phase 3 LEGA trial including 169 chemotherapy-naive patients with HER2-negative gastric cancer who were randomly assigned to receive either EOX or a docetaxel, oxaliplatin, and capecitabine regimen.
Disclosures: No funding source was identified for this work. The authors reported no competing interests.
Source: Rosati G et al. A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: The LEGA trial. Gastric Cancer. 2022 (Mar 30). Doi: 10.1007/s10120-022-01292-y
Key clinical point: Replacing anthracycline with fractional docetaxel in the epirubicin, oxaliplatin, and capecitabine (EOX) regimen does not improve survival and increases toxicities in chemotherapy-naive patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer.
Major finding: At data cutoff of interim analysis, no significant difference was reported between the two treatment groups in progression-free survival (hazard ratio [HR] 0.975; P = .885) and overall survival (HR 1.002; P = .992). Treatment modification (91% vs. 78%; P = .017) and grade ≥3 adverse event rates (51% vs. 43%) were higher in the docetaxel vs. EOX group.
Study details: This study was a randomized, parallel group, open-label phase 3 LEGA trial including 169 chemotherapy-naive patients with HER2-negative gastric cancer who were randomly assigned to receive either EOX or a docetaxel, oxaliplatin, and capecitabine regimen.
Disclosures: No funding source was identified for this work. The authors reported no competing interests.
Source: Rosati G et al. A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: The LEGA trial. Gastric Cancer. 2022 (Mar 30). Doi: 10.1007/s10120-022-01292-y
Key clinical point: Replacing anthracycline with fractional docetaxel in the epirubicin, oxaliplatin, and capecitabine (EOX) regimen does not improve survival and increases toxicities in chemotherapy-naive patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer.
Major finding: At data cutoff of interim analysis, no significant difference was reported between the two treatment groups in progression-free survival (hazard ratio [HR] 0.975; P = .885) and overall survival (HR 1.002; P = .992). Treatment modification (91% vs. 78%; P = .017) and grade ≥3 adverse event rates (51% vs. 43%) were higher in the docetaxel vs. EOX group.
Study details: This study was a randomized, parallel group, open-label phase 3 LEGA trial including 169 chemotherapy-naive patients with HER2-negative gastric cancer who were randomly assigned to receive either EOX or a docetaxel, oxaliplatin, and capecitabine regimen.
Disclosures: No funding source was identified for this work. The authors reported no competing interests.
Source: Rosati G et al. A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: The LEGA trial. Gastric Cancer. 2022 (Mar 30). Doi: 10.1007/s10120-022-01292-y